BioIncept, founded in 2001, is a clinical-stage privately held company committed to the development of transformative therapeutic and diagnostic products based on the discovery of the PreImplantation Factor (PIF).
Naturally occurring in mammalian embryos, PIF has broad regulatory implications in pregnancy, immunity, inflammation and transplant. Synthetic human-grade PIF (sPIF) was developed to translate the PIF effect for intended use in clinical trials and, ultimately, in commercial drug products.
BioIncept pursues and prioritizes development of sPIF in clinical indications with high unmet need that are commercially attractive. The company is working closely with key opinion leaders globally from across the PIF platform of disciplines.
A completed First-in-Human (FIH) university-sponsored clinical trial in an orphan autoimmune disease (NCT02239562) supports sPIF non-toxicity and unique safety profile. Fast-Track and several Orphan Drug designations have been awarded by the United States Food & Drug Administration (FDA). BioIncept is currently preparing for further trials on the registrational path in focus indications.
With a top-tier management team, a global network of scientific collaborators and a robust intellectual property portfolio and patent estate, BioIncept is well positioned to achieve its mission of delivering on the promise of PIF for patients with significant unmet medical needs.
BioIncept Co-Founder and Chief Scientific Officer Eytan Barnea holds the Markku Seppala Ovidon Lecture on “Successful embryo-maternal interface: from nature to clinic“ as plenary speaker at the 12th FIGO World Congress of Gynecology and Obstetrics in Brazil.